Jane Street’s Atea Pharmaceuticals AVIR Stock Holding History

Jane Street’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-177,700	Closed	-$855K	–	8996
2022 Q4	$855K	Sell	177,700 -8,200	-4%	-$41.5K	﹤0.01%	5228
2022 Q3	$1.06M	Buy	185,900 +9,800	+6%	+$75K	﹤0.01%	5314
2022 Q2	$1.25M	Buy	176,100 +88,500	+101%	+$604K	﹤0.01%	5060
2022 Q1	$632K	Sell	87,600 -137,300	-61%	-$932K	﹤0.01%	7039
2021 Q4	$2.01M	Buy	224,900 +206,100	+1,096%	+$3.21M	﹤0.01%	4481
2021 Q3	$659K	Sell	18,800 -100	-0.5%	-$2.77K	﹤0.01%	6754
2021 Q2	$406K	Buy	+18,900	New	+$568K	﹤0.01%	7631

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jane Street's AVIR Position: Q1 2026 in Review

Jane Street increased its Atea Pharmaceuticals (AVIR) stake by 67% in Q1 2026, buying an estimated $770K and bringing the position to 418,296 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #4862.

Jane Street first reported a position in AVIR in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.61M in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

Jane Street held 418,296 shares of Atea Pharmaceuticals worth $2.25M as of Q1 2026.
Jane Street bought 167,591 Atea Pharmaceuticals shares in Q1 2026, an estimated $770K.
Atea Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4862 holding.
Jane Street first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
Jane Street's Atea Pharmaceuticals position peaked at $2.61M in Q3 2021.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.